https://www.selleckchem.com/pr....oducts/sacituzumab-g
Given the lower incidence of ARF and delayed sternal closure in the postoperative period and similar midterm outcomes, we believe that the BH strategy is preferable. Both strategies were associated with satisfactory midterm prevention of reintervention and reoperation. Given the lower incidence of ARF and delayed sternal closure in the postoperative period and similar midterm outcomes, we believe that the BH strategy is preferable. Reintervention after transcatheter edge to edge repair using MitraClip is still challenging.
Like
Comment
Share
